GORING-ON-THAMES, England, August 21 /PRNewswire/ -- The world's leading provider of innovative cognitive function assessment technology, Cognitive Drug Research (CDR) has announced their United States incorporation in the State of Illinois. The move strengthens CDR's already significant presence in the US and offers greater convenience to US clients in terms of both logistics and business operations. To coincide with this incorporation and to facilitate enhanced service in this market, CDR is pleased to announce the appointment of Steven T. Satek, BS, MBA as Vice President, Business Development for North America, who will spearhead US business activities.
Mr. Satek brings more than 15 years of clinical research experience to the CDR team and has held senior management positions at Comprehensive NeuroScience, Radiant Research, Protocare Trials and the Chicago Center for Clinical Research. Throughout his career, Mr. Satek has demonstrated success in both strategic development and key operations roles. Specializing in Central Nervous System research, Mr. Satek has developed and administered successful expansion of established clinical research sites that focused on comprehensive training and open, honest dialog with leading industry sponsors.
"Steve brings to the CDR team notable depth and breadth of knowledge and experience in the areas of business development and operational guidance" said Professor Keith Wesnes, Chief Executive and Founder of Cognitive Drug Research. "Knowing Steve for many years, I have been impressed with his ability to successfully blend his extensive knowledge of the research industry with the specific and unique needs of clients. His appointment further strengthens CDR's dedication to rapidly and thoroughly address the needs of our current North American clients and to educate new customers on the importance of validated cognitive testing across a variety of therapeutic indications."
The new office in Chicago will also be the operational hub in the US for CDR's core business of providing automated cognition assessment services in clinical trials. Suzie Fairley, Senior Researcher, will be the permanent dedicated key point of contact for North American studies. The selection of Chicago as the preferred location will therefore provide convenient, rapid and centralized service to all regions of the United States and North America.
About CDR
Cognitive Drug Research Ltd (CDR) was formed in 1986 and is the world's leading provider of innovative cognitive function assessment technology to the pharmaceutical industry. The CDR system has been used in over 1000 sites around the world and has been involved in over 500 clinical trials, across all phases in a vast array of indications. CDR's solution combines the most accurate testing technology available with unrivaled expert analysis and interpretation of results. The CDR system is bidirectionally sensitive to alterations in cognitive function produced by pharmaceutical and neutraceutical compounds, ageing and disease. The system is supported by an extensive database, available 45 languages and all data processing is FDA 21 CFR Part 11 compliant, meeting GCP requirements. It is the subject of over 170 peer-reviewed papers and chapters.
Contact: Professor Keith A. Wesnes Chief Executive COGNITIVE DRUG RESEARCH LTD +44-(0)1491-878700 Steven T. Satek Vice President, Business Development COGNITIVE DRUG RESEARCH INC +1-(773)-293-4053 For more information about CDR please visit www.cognitivedrugresearch.com
Cognitive Drug Research LtdCONTACT: Contact: Professor Keith A. Wesnes, Chief Executive, COGNITIVEDRUG RESEARCH LTD, +44-(0)1491-878700. Steven T. Satek, Vice President,Business Development, COGNITIVE DRUG RESEARCH INC, +1-(773)-293-4053
